Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Tax Provisions (2022 - 2025)

Historic Tax Provisions for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$5.0 million.

  • Indivior Pharmaceuticals' Tax Provisions fell 16250.0% to -$5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.0 million, marking a year-over-year increase of 70909.09%. This contributed to the annual value of $13.0 million for FY2024, which is 16842.11% up from last year.
  • Indivior Pharmaceuticals' Tax Provisions amounted to -$5.0 million in Q3 2025, which was down 16250.0% from $44.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Tax Provisions' 5-year high stood at $73.0 million during Q4 2022, with a 5-year trough of -$23.0 million in Q2 2023.
  • Moreover, its 4-year median value for Tax Provisions was $1.5 million (2024), whereas its average is $8.2 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first surged by 45384.62% in 2023, then plummeted by 16250.0% in 2025.
  • Indivior Pharmaceuticals' Tax Provisions (Quarter) stood at $73.0 million in 2022, then crashed by 109.59% to -$7.0 million in 2023, then skyrocketed by 342.86% to $17.0 million in 2024, then crashed by 129.41% to -$5.0 million in 2025.
  • Its Tax Provisions was -$5.0 million in Q3 2025, compared to $44.0 million in Q2 2025 and $11.0 million in Q1 2025.